CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- 3 Insider Initial Statement of Ownership
- D Other Notice of Sales of Unregistered Securities
- 8-K Event Executive or director change
- 8-K Event Material agreement · Unregistered share sale
- 424B5 Offering Prospectus
- 8-K Event Regulation FD disclosure
- 8-K Event Other events
- 8-K Event Material agreement · Other events
- S-1 Offering Registration Statement
- 8-K Event Material agreement · Unregistered share sale · Executive or director change
- 4 Open-market buy CEO bought 21,000 shares at an average $0.93 ($19,540)
- 8-K Event Material agreement · Agreement ended · New debt or obligation
- 8-K Event Regulation FD disclosure
- 10-Q Report Quarterly Report
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-3 Offering Registration Statement
- 8-K Event Executive or director change · Shareholder vote results
Page 5 of 38 · 746 filings